To include your compound in the COVID-19 Resource Center, submit it here.

Adcetris gets Priority Review for first-line classical Hodgkin's lymphoma

Seattle Genetics (NASDAQ:SGEN) said FDA accepted and granted Priority Review to an sBLA for Adcetris brentuximab vedotin (SGN-35) as

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE